The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
